KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $285,581 | -73.5% | 8,958 | -66.6% | 0.00% | -75.0% |
Q2 2023 | $1,078,351 | -32.9% | 26,838 | -28.6% | 0.00% | -42.9% |
Q1 2023 | $1,605,990 | +157.7% | 37,611 | +189.8% | 0.01% | +133.3% |
Q4 2022 | $623,300 | -24.7% | 12,980 | -41.0% | 0.00% | -40.0% |
Q3 2022 | $828,000 | -44.5% | 22,016 | -59.3% | 0.01% | -54.5% |
Q2 2022 | $1,493,000 | – | 54,031 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
Atom Investors LP | 49,981 | $3,526,000 | 0.36% |